Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T17:36:55.702Z.
Calculation as of: 2026-10-06T17:36:55.702Z.
Quote observation: 2026-10-06T17:32:54.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8a37bf5da35164cf1f35689d787409f81d347c26e3158920307b7793dc95150d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$59.34M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$57.09M
EV/Sales Ratio
56347.56x
TTM Avg
24657.57x
3Y Avg
9404.59x
5Y Avg
5624.70x
Market Cap
$59.86M
EV/Sales Ratio
N/A
TTM Avg
236.83x
3Y Avg
178.58x
5Y Avg
259.06x
Market Cap
$60.29M
EV/Sales Ratio
N/A
TTM Avg
10156.67x
3Y Avg
5697.35x
5Y Avg
5697.35x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | $59.16M | N/A | N/A | N/A | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $59.33M | N/A | N/A | N/A | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $59.34M | N/A | N/A | N/A | N/A |
| Talphera, Inc. (TLPH)vs › | $57.09M | 56347.56x | 24657.57x | 9404.59x | 5624.70x |
| Adicet Bio, Inc. (ACET)vs › | $59.66M | N/A | 8.16x | 93.50x | 96.95x |
| Oncolytics Biotech Inc. (ONCY)vs › | $59.86M | N/A | 236.83x | 178.58x | 259.06x |
| OKYO Pharma Limited (OKYO)vs › | $56.78M | N/A | N/A | N/A | N/A |
| Fractyl Health, Inc. (GUTS)vs › | $60.29M | N/A | 10156.67x | 5697.35x | 5697.35x |
| Kalaris Therapeutics Inc (KLRS)vs › | $61.17M | N/A | N/A | N/A | N/A |
| Xilio Therapeutics, Inc. (XLO)vs › | $61.35M | N/A | 0.38x | 1.19x | 1.19x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
